Read Time:13 Second
Lupin Limited has informed the Exchange regarding a press release dated November 14, 2025, titled “Lupin Launches Risperidone Long-Acting Injectable with 180-day CGT exclusivity in the U.S., the First Product from its Proprietary Long-Acting Injectable Platform PrecisionSphere”. |SUBJECT: Press Release
Happy
0
0 %
Sad
0
0 %
Excited
0
0 %
Sleepy
0
0 %
Angry
0
0 %
Surprise
0
0 %